Background: Due to the lack of high-level data, there is still controversy over the oncological safety of breast conservation in patients with centrally located breast cancer. This study aimed to assess the safety of breast-conserving surgery in patients with centrally located breast cancer based on the data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods:We collected data for all cases diagnosed with breast cancer who underwent breast-conserving surgery from 2012-2014 in the SEER database. The primary outcome of our study was disease-specific survival (DSS) and overall survival (OS). The PSM was used to eliminate the effects of non-random statistics.Chi-square test, Kaplan-Meier method and Cox proportional hazards regression model on univariate and multivariate analysis were used to analyze the data.Results: Data from 79,214 patients who had undergone breast-conserving surgery were analyzed in this study, including those with breast cancer in the central region (n=3,128) and outside the central region (n=76,086). The DSS of central breast cancer patients and outside the central breast cancer patients was 58.1 months versus 58.0 months (P>0.05), respectively, while the OS of the 2 groups was 58.0 months versus 58.0 months (P>0.05), respectively.Conclusions: Breast cancer in the central region should not be contraindicated for breast conserving surgery and breast-conserving surgery can benefit a wider range of patients.

Objective To inquire into the influence of the pelvic floor reconstruction surgery of pelvic organ prolapse on Papillomavirus-Negative atypical squamous cells of undetermined significance cytology. Methods This investigation was studied retrospectively about female patients of POP 3~4 stage with high-risk human papillomavirus DNA-negative ASCUS between January, 2008 and September, 2018.All patients received one of two treatment regimens, pelvic floor reconstruction or local hydrocortisone cream(0.1% Hydrocortisone Butyrate cream, 1g nightly for no less than 12 weeks). After 6 months follow-up, we collected data to compare the positive rate of ASCUS with high-risk human papillomavirus DNA-negative between the two groups after intervention. Results The negative conversion rate of ASCUS in the operative patients was higher than in patients using local hydrocortisone cream (33/47 [70.2%] vs 19/44 [43.2%], P = 0.009). Conclusions The decline of non–human papillomavirus ASCUS cytology in postoperative patients might be related to pelvic floor reconstruction.